Mechanisms of new targeted drugs in follicular lymphoma and clinical options / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 441-444, 2021.
Article
Dans Chinois
| WPRIM
| ID: wpr-907196
ABSTRACT
Follicular lymphoma is the most common indolent lymphoma. At present, it is commonly treated with immunochemotherapy, but the prognosis of patients with progression and relapse is still poor. New targeted drugs include cell surface antibodies, immunomodulators, cell signaling pathway kinase inhibitors, and chimeric antigen receptor T cell therapy and dendritic cell vaccines have greatly extended the survival period of these patients and provided more options for clinical treatment.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Leukemia & Lymphoma
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS